Literature DB >> 33280488

Cerebral Blood Flow and Cognitive Performance in Postural Tachycardia Syndrome: Insights from Sustained Cognitive Stress Test.

Rachel Wells1,2, Varun Malik1,3, Anthony G Brooks1, Dominik Linz1,3, Adrian D Elliott1, Prashanthan Sanders1,3, Amanda Page4, Mathias Baumert1,5, Dennis H Lau1,3.   

Abstract

Background The physiology underlying "brain fog" in the absence of orthostatic stress in postural tachycardia syndrome (POTS) remains poorly understood. Methods and Results We evaluated cognitive and hemodynamic responses (cardiovascular and cerebral: heart rate, blood pressure, end-tidal carbon dioxide, and cerebral blood flow velocity (CBFv) in the middle cerebral artery at baseline, after initial cognitive testing, and after (30-minutes duration) prolonged cognitive stress test (PCST) whilst seated; as well as after 5-minute standing in consecutively enrolled participants with POTS (n=22) and healthy controls (n=18). Symptom severity was quantified with orthostatic hypotensive questionnaire at baseline and end of study. Subjects in POTS and control groups were frequency age- and sex-matched (29±11 versus 28±13 years; 86 versus 72% women, respectively; both P≥0.4). The CBFv decreased in both groups (condition, P=0.04) following PCST, but a greater reduction in CBFv was observed in the POTS versus control group (-7.8% versus -1.8%; interaction, P=0.038). Notably, the reduced CBFv following PCST in the POTS group was similar to that seen during orthostatic stress (60.0±14.9 versus 60.4±14.8 cm/s). Further, PCST resulted in greater slowing in psychomotor speed (6.1% versus 1.4%, interaction, P=0.027) and a greater increase in symptom scores at study completion (interaction, P<0.001) in the patients with POTS, including increased difficulty with concentration. All other physiologic responses (blood pressure and end-tidal carbon dioxide) did not differ between groups after PCST (all P>0.05). Conclusions Reduced CBFv and cognitive dysfunction were evident in patients with POTS following prolonged cognitive stress even in the absence of orthostatic stress.

Entities:  

Keywords:  cerebral blood flow; cognitive dysfunction; orthostatic intolerance; postural tachycardia syndrome; transcranial doppler

Year:  2020        PMID: 33280488     DOI: 10.1161/JAHA.120.017861

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  6 in total

1.  RT-QUiC in multiple system atrophy: the biomarker of the future? and other updates on recent autonomic research.

Authors:  Mitchell G Miglis; Nicholas Larsen; Srikanth Muppidi
Journal:  Clin Auton Res       Date:  2021-01-29       Impact factor: 4.435

Review 2.  Faintly tired: a systematic review of fatigue in patients with orthostatic syncope.

Authors:  Ryan E Y Wu; Farhaan M Khan; Brooke C D Hockin; Trudie C A Lobban; Shubhayan Sanatani; Victoria E Claydon
Journal:  Clin Auton Res       Date:  2022-06-10       Impact factor: 5.625

3.  Orthostatic Intolerance in Adults Reporting Long COVID Symptoms Was Not Associated With Postural Orthostatic Tachycardia Syndrome.

Authors:  Ann Monaghan; Glenn Jennings; Feng Xue; Lisa Byrne; Eoin Duggan; Roman Romero-Ortuno
Journal:  Front Physiol       Date:  2022-03-04       Impact factor: 4.566

4.  Stellate ganglion block reduces symptoms of Long COVID: A case series.

Authors:  Luke D Liu; Deborah L Duricka
Journal:  J Neuroimmunol       Date:  2021-12-08       Impact factor: 3.478

5.  Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: a prospective multidomain observational study.

Authors:  Alex Buoite Stella; Giovanni Furlanis; Nicolò Arjuna Frezza; Romina Valentinotti; Milos Ajcevic; Paolo Manganotti
Journal:  J Neurol       Date:  2021-08-12       Impact factor: 4.849

6.  Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  C Linda M C van Campen; Peter C Rowe; Frans C Visser
Journal:  Medicina (Kaunas)       Date:  2021-12-24       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.